The Molecule That Accidentally Exposed the Limits of the Tablet
Swallow a standard ibuprofen tablet for a headache, and for the next hour, nothing happens where it matters. The tablet is still travelling to the stomach, still breaking apart, still dissolving — and the pain doesn’t start easing until enough of the drug has actually crossed into the blood to do something about it.
Ibuprofen doesn’t prove tablets work well. It proves how forgiving a molecule has to be for tablets to work at all.
In a category where most drugs struggle with absorption, variability and delayed onset, ibuprofen is the exception. It is fast, reliable, and forgiving — a reputation earned almost entirely by the molecule, not by the format it happens to be sold in.
A molecule built for the wrong system — but surviving it
Ibuprofen succeeds because of its chemistry, not its delivery. It is classified as a BCS Class II compound: low aqueous solubility, but high intestinal permeability. Once it is in solution, the body absorbs it easily — the difficulty was never crossing the gut wall, only getting the drug dissolved in the first place. Its pharmacokinetics compound the forgiveness: a short elimination half-life of 1.8 to 2.0 hours means plasma concentrations rise and fall predictably, and a wide therapeutic window means minor variation in dose or timing rarely matters clinically. Ibuprofen is, chemically, about as easy a drug as pharma gets to formulate badly and still have work.
The illusion of good tablet performance
Because ibuprofen performs well in a tablet, it is tempting to conclude that tablets perform well. They don’t — ibuprofen is the exception, not the proof. Most oral drugs dissolve more slowly, absorb less predictably, or degrade before they reach circulation. Ibuprofen doesn’t validate the tablet as a delivery system. It just happens to be forgiving enough to survive one.
Where the tablet still fails ibuprofen
Even a compound this forgiving isn’t immune to the format’s friction. A tablet has to disintegrate before dissolution can begin, which delays onset and introduces variability between individual tablets. Gastric emptying and food intake shift how quickly that disintegration happens, so identical tablets taken with or without food behave differently in the same person. And different patients absorb at different rates — the same dose can produce meaningfully different peak concentrations from one person to the next.
What happens when you remove the tablet
A 2017 randomised crossover study gave the same 200mg dose of ibuprofen to the same healthy volunteers in three formulations: a standard tablet, a liquid-filled softgel capsule, and an arginine salt tablet. The standard tablet reached peak plasma concentration in roughly 75 minutes. The liquid-filled capsule reached it in about 30 — with a higher peak concentration as well. Same molecule, same dose, same people. The only variable was whether the drug still had to dissolve, or arrived already dissolved.
That is the entire tablet tax on ibuprofen: roughly 45 minutes, in a molecule about as forgiving as oral pharmacology gets. Liquid formulations remain mostly reserved for children not because they perform worse, but because they are harder to manufacture — suspension stability, taste-masking and shelf life are all genuinely difficult problems. The industry defaulted to tablets because tablets were easier to make, not because they were the better way to get a drug into a patient.
The real question
Ibuprofen gets away with losing forty-five minutes to its own dosage form because it can afford to. Most molecules cannot. A drug with a narrower therapeutic window, a shorter effective half-life, or less forgiving absorption kinetics doesn’t have that luxury — and unlike ibuprofen, most of that lost time is never measured, because there’s no forgiving molecule around to expose it.
The lesson isn’t really about ibuprofen. It’s about what a well-behaved, decades-old molecule reveals about the format built around it: the tablet was never optimised for the drug. The drug was optimised to survive the tablet. The delivery system should adapt to the molecule — not the other way round.
Ibuprofen doesn’t prove tablets work. It proves how forgiving a molecule has to be for one to work at all. This isn’t a success story for the tablet. It’s a warning for every less forgiving drug still riding on one.
Part of the Ibumix series on bioavailability. Start with the overview: Bioavailability: the medicine that never arrives.
Sources
- Shin D, Lee SJ, Ha Y-M, et al. (2017). Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen. Drug Design, Development and Therapy, 11, 135–141. pmc.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Ibuprofen tablets, prescribing information, Clinical Pharmacology section. accessdata.fda.gov
- Potthast H, Dressman JB, Junginger HE, et al. (2005). Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen. Journal of Pharmaceutical Sciences, 94(10), 2121–2131. doi.org/10.1002/jps.20444